Novo Holdings’ portfolio company VectivBio goes public

Novo Holdings’ portfolio company VectivBio goes public

Date
April 13, 2021

Novo Ventures, the ventures arm of Novo Holdings, is pleased to note the $146.6 million Initial Public Offering on NASDAQ of its portfolio company VectivBio Holdings AG [VECT]. VectivBio is a Swiss company focused on the development of Apraglutide, a next-generation, long-acting, synthetic GLP-2 analog for short bowel syndrome, currently in Phase 3 clinical development.

For further information, please find the full statement here.